Beijing Silian Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical enterprise integrating R & D, production and marketing. It is the largest manufacturer in the field of folic acid in China and a national high-tech enterprise. Srian pharmaceutical was founded by Beijing chuangying technology industry group. Its business covers reproductive health, maternal and child health care, orthopedics, oncology, gynecology, pediatrics, geriatrics and many other fields. The company's headquarters is now located in Beijing Economic and Technological Development Zone, and its business covers more than 700 cities in 30 provinces, cities and autonomous regions in China. The core variety of Sri an pharmaceutical industry, "Sri an folic acid tablets", is a scientific research achievement made by the Chinese and American governments after 13 years of cooperation, at a cost of US $20 million and through 250000 medical observations. This achievement has been adopted by more than 50 countries in the world and has been published in the lancet, New England Journal of medicine, Chinese Journal of medicine Chinese Journal of epidemiology and other famous academic journals at home and abroad. As early as 1997, "Silian folic acid tablets" obtained the new drug certificate and production approval issued by the Ministry of health, and became the first 0.4mg folic acid tablets listed in the world. Its quality standard has been set as the international standard by the World Health Organization and included in the Chinese Pharmacopoeia. As a key project of "one hundred scientific and technological achievements in ten years" of the Ministry of health, Sri an folic acid tablets has been promoted to the whole country, and has been rated as "national key new product" by five ministries and commissions including the Ministry of science and technology and the Ministry of Commerce. Srian pharmaceutical always adheres to the road of "innovation and revitalizing the enterprise through science and technology", increasing R & D investment year by year to enhance the ability of independent innovation. The R & D achievements have been gradually transformed into the enterprise's independent intellectual property rights and core technology. At present, srian pharmaceutical has obtained nearly 100 patents, including more than 30 invention patents, A large number of new drugs such as "naoqingzhiming tablet" have been successfully developed to prevent Alzheimer's disease. The company has always focused on the fields of maternal, child and chronic diseases of the elderly. Now it has many big health products, such as Kingsley multi dimension tablets, pregnant women's calcium, DHA algal oil milk calcium powder, pregnant women's special shampoo and shower gel, pregnant women's toothpaste and so on. Based on the enterprise's long-term development strategy, in order to further improve the company's production scale, product quality level and R & D strength, Sri an pharmaceutical has invested and built a production and R & D base in Zhongguancun National Independent Innovation Demonstration Zone • Beijing Daxing biomedical industry base, as well as a National Development Zone • national new industrialization industry demonstration base • Cangzhou Lingang Economic and Technological Development Zone, Hebei Province, In 2018, it invested and built a raw material production and R & D base.